Alexandria Real Estate Equities Faces Class Action Lawsuit with Deadline for Claims on January 26, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 10 2026
0mins
Source: PRnewswire
- Lawsuit Notification: ClaimsFiler reminds investors that those who purchased Alexandria Real Estate Equities securities between January 27, 2025, and October 27, 2025, must file lead plaintiff applications by January 26, 2026, to participate in the class action lawsuit against the company.
- Financial Missteps: Alexandria's third-quarter financial results for 2025 fell short of expectations, leading to a reduction in full-year FFO guidance primarily due to lower occupancy rates and sluggish leasing activity, resulting in a significant real estate impairment charge of $323.9 million, which undermines investor confidence.
- Stock Price Plunge: Following the earnings report on October 27, 2025, Alexandria's share price plummeted from $77.87 to $62.94, marking a nearly 19% decline in just one day, reflecting market concerns regarding the company's financial health.
- Legal Implications: The lawsuit alleges that Alexandria and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to greater legal and financial risks.
Analyst Views on ARE
Wall Street analysts forecast ARE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARE is 51.53 USD with a low forecast of 15.84 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
4 Buy
11 Hold
0 Sell
Moderate Buy
Current: 57.890
Low
15.84
Averages
51.53
High
67.00
Current: 57.890
Low
15.84
Averages
51.53
High
67.00
About ARE
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
